News Search

Columbia's Eleanor and Lou Gehrig MDA/ALS Center, legacy of baseball great, focuses on patient care and clinical trials.

Target ALS, a consortium of at least 18 laboratories, including ones at CUMC and at Johns Hopkins, will work to find biological “targets,” that could be used to test potential drug therapies for ALS. CUMC's Christopher E. Henderson is Target ALS's scientific director.

CUMC neuroscientist Asa Abeliovich and his team have identified a protein trafficking defect within brain cells that may underlie common non-familial forms of Parkinson's disease.